TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02882022

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure
Description: A CPAP machine will be used to deliver positive pressure at various levels after which middle ear pressure and ear drums will be evaluated for changes.
Study: NCT04019210

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MODIFIED TRABECULECTOMY
Description: Rectangular scleral flap
Study: NCT03012594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanreotide
Description: Dosage: 120mg Dosage form: subcutaneous injection, pre-filled syringe Dosage frequency: 3 injections over 12 weeks, each dose administered 4 weeks apart
Study: NCT00278863

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-1
Study: NCT00701675

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 50 or 100 mg
Description: 50mg or 100mg matching placebo
Study: NCT04774328

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CA-008 (vocacapsaicin)
Description: Single administration of CA-008 (vocacapsaicin) versus placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single administration of CA-008 (vocacapsaicin) versus placebo
Study: NCT02790203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: NSAIDS
Study: NCT00278863

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Study: NCT02384993

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Physical Activity
Description: This is a 26-week aerobic exercise intervention. The primary mode of training is treadmill walking, with the initial speed and duration calibrated to each participant's baseline aerobic capacity. Participants will train 3-4 days per week with the goal of attaining 150+ minutes of exercise per week by the seventh week. Exercise will be set between 50-60% of maximum heart rate reserve for weeks 1-4, 60-70% for weeks 5-8, and 70-80% for weeks 9-26. Exercise duration will be approximately 15-20 minutes per session during the first week and then increase by 5 minutes each week until a duration of approximately 38-50 minutes per session is reached. Each training session will begin with a 5-minute warm-up and end with a 5-minute recovery period.
Study: NCT01810380

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily as tablets and capsules, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Description: 2-4 mg/day, once daily, tablets, orally

Intervention type: DRUG
Group type: OTHER
Intervention: Quetiapine extended release
Description: 400-800 mg/day, once daily, encapsulated tablets, orally
Study: NCT04262908

Intervention type: OTHER
Intervention: Telephone call
Description: Patients who did not return to work after the SL prescribed initially and had an extension of the SL will be called at 4 months postoperatively to collect infomation
Study: NCT01482572

Intervention type: PROCEDURE
Intervention: biopsy
Description: percutaneous lung biopsy and aspiration
Study: NCT04486612

Intervention type: OTHER
Intervention: spinal anesthesia
Description: prospective observational study

Intervention type: OTHER
Intervention: spinal anesthesia
Description: prospective observational study
Study: NCT01126684

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: 10 mg of atorvastatin once daily for six months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo once daily for six months
Study: NCT01617928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: veliparib (ABT-888)
Description: Dosing orally twice daily starting Day 1 through day 7 of each cycle. Decisions to move to the next cohort will be based on evaluation of DLTs in the current cohort. Decisions will be made with a discussion between the Sponsor and the principal investigator to dose escalate or de-escalate or add more subjects to the cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Carboplatin will be administered on Day 3 of each cycle, intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Paclitaxel will be administered on Day 3 of each cycle, intravenously.
Study: NCT03491969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpha-Lipoic Acid(α-LA)
Description: 200 mg, po, tid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: 200 mg, po, tid
Study: NCT02944513

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Quell
Study: NCT00531908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: furosemide
Description: furosemide
Study: NCT02818270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol
Description: Salbutamol (albuterol ) was delivered by a jet nebulizer with a 50 pis oxygen flow at 6 L/min.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylcysteine
Description: Acetylcystine was delivered by a jet nebulizer with a 50 pis oxygen flow at 6 L/min.
Study: NCT01154907

Intervention type: DRUG
Intervention: Praziquantel
Description: One day, 40mg/kg standard mass Praziquantel as recommended by WHO and local authorities

Intervention type: DRUG
Intervention: Praziquantel
Description: One day, 40mg/kg standard mass Praziquantel as recommended by WHO and local authorities
Study: NCT03542149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 480 mg Piperaquine phosphate
Description: 480 mg Piperaquine is a bis 4-aminoquinoline and was used mainly in China from the 1960's to the 1980's as an antimalarial monotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 480 mg Piperaquine phosphate
Description: 480 mg Piperaquine is a bis 4-aminoquinoline and was used mainly in China from the 1960's to the 1980's as an antimalarial monotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 640 mg Piperaquine phosphate
Description: 640 mg Piperaquine is a bis 4-aminoquinoline and was used mainly in China from the 1960's to the 1980's as an antimalarial monotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 640 mg Piperaquine phosphate
Description: 640 mg Piperaquine is a bis 4-aminoquinoline and was used mainly in China from the 1960's to the 1980's as an antimalarial monotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 640 mg Piperaquine phosphate
Description: 640 mg Piperaquine is a bis 4-aminoquinoline and was used mainly in China from the 1960's to the 1980's as an antimalarial monotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 mg OZ 439
Description: 200 mg OZ439 + α-tocopherol polyethylene glycol 1000 succinate (TPGS) granules for oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 mg OZ 439
Description: 200 mg OZ439 + α-tocopherol polyethylene glycol 1000 succinate (TPGS) granules for oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 400 mg OZ 439
Description: 400 mg OZ439 + α-tocopherol polyethylene glycol 1000 succinate (TPGS) granules for oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 400 mg OZ 439
Description: 400 mg OZ439 + α-tocopherol polyethylene glycol 1000 succinate (TPGS) granules for oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 400 mg OZ 439
Description: 400 mg OZ439 + α-tocopherol polyethylene glycol 1000 succinate (TPGS) granules for oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 800 mg OZ 439
Description: 800 mg OZ439 + α-tocopherol polyethylene glycol 1000 succinate (TPGS) granules for oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 800 mg OZ 439
Description: 800 mg OZ439 + α-tocopherol polyethylene glycol 1000 succinate (TPGS) granules for oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 960 mg PQP
Description: 960 mg Piperaquine is a bis 4-aminoquinoline and was used mainly in China from the 1960's to the 1980's as an antimalarial monotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 320 mg PQP
Description: 320 mg Piperaquine is a bis 4-aminoquinoline and was used mainly in China from the 1960's to the 1980's as an antimalarial monotherapy.
Study: NCT02356328

Intervention type: DEVICE
Intervention: NovaTears® Eye Drops
Description: Topical eye drops for lubrication of the ocular surface
Study: NCT02953067

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open reduction and internal fixation
Description: Stratum 1: Conservative treatment versus open reduction and internal fixation Stratum 2: Open reduction and internal fixation versus arthrodesis

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Primary arthrodesis
Description: Primary arthrodesis versus ORIF

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conservative treatment
Description: Conservative treatment versus open reduction and internal fixation
Study: NCT03006900

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates
Description: Pilates

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Massage
Description: Massage

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage
Description: Massage
Study: NCT01234519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AEZS-108
Description: 128, 160, 210 or 267 mg/m2, 2-hour intravenous (IV) infusion, Day 1 of 21-day cycles , until toxicity or progression, up to 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AEZS-108
Description: 128, 160, 210 or 267 mg/m2, 2-hour intravenous (IV) infusion, Day 1 of 21-day cycles , until toxicity or progression, up to 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AEZS-108
Description: 128, 160, 210 or 267 mg/m2, 2-hour intravenous (IV) infusion, Day 1 of 21-day cycles , until toxicity or progression, up to 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AEZS-108
Description: 128, 160, 210 or 267 mg/m2, 2-hour intravenous (IV) infusion, Day 1 of 21-day cycles , until toxicity or progression, up to 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AEZS-108 at MTD
Description: 2-hour IV infusion, Day 1 of 21-day cycles , until toxicity or progression, up to 6 cycles
Study: NCT02398721

Intervention type: OTHER
Group type: OTHER
Intervention: Fine Needle Aspiration Cytology
Study: NCT02435095

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maintenance treatment
Description: Treatment with antipsychotic drug (either second-generation antipsychotics or low-dose first generation antipsychotics) for at least 12 months.~All antipsychotics approved in Germany are permitted (amisulpride, aripiprazole, benperidol, bromperidol, chlorprothixene, clozapine, flupentixole, fluphenazine, fluspirilene, haloperidol, levomepromazine, loxapine, lurasidone, melperone, olanzapine, paliperidone, perazine, perphenazine, pimozide, pipamperone, prothipendyl, quetiapine, risperidone, sertindole, sulpiride, thioridazine, ziprasidone, zuclopenthixole).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intermittent treatment
Description: Treatment with antipsychotic drug (either second-generation antipsychotics or low-dose first generation antipsychotics) only for first episode of schizophrenia, tapering-off medication after remission of positive symptoms, reinstatement of treatment only in case of recurrence of positive symptoms.~All antipsychotics approved in Germany are permitted (amisulpride, aripiprazole, benperidol, bromperidol, chlorprothixene, clozapine, flupentixole, fluphenazine, fluspirilene, haloperidol, levomepromazine, loxapine, lurasidone, melperone, olanzapine, paliperidone, perazine, perphenazine, pimozide, pipamperone, prothipendyl, quetiapine, risperidone, sertindole, sulpiride, thioridazine, ziprasidone, zuclopenthixole).
Study: NCT01584453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Nitrite
Description: A bolus of sodium nitrite solution (1.8 micromol in 10 ml PRe-diluted in 0.9% sodium chloride in a syringe) will be delivered over 30-60 seconds via intracoronary injection initiated during the re-establishment of antegrade epicardial flow with PPCI.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride Placebo
Description: The control intervention is a bolus of 0.9% sodium chloride solution (prepared with an identical appearance to the sodium nitrite).
Study: NCT01053234

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Standardised meals

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Standardised meals
Study: NCT03892993

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision Aid
Description: Use decision aid

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03857061

Intervention type: DEVICE
Intervention: smartphone, smartwatch, WearCOPDv2 application
Description: WearCOPD2 consists of hardware and software components.~6.1 Hardware The hardware for wearCOPDv2 consists of three main components; (1) a smartwatch, (2) a phone, and (3) a server.~6.2 Software~The wearCOPDv2 system has two main software components:~1. Data collection service~2. Participant user interface
Study: NCT04402632

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Management
Description: SDH Evacuation (Control)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surgical Management + Treatment
Description: SDH Evacuation + Onyx™ LES Embolization

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Treatment
Description: Observation Only (Control)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment
Description: Onyx™ LES Embolization
Study: NCT01492036

Intervention type: OTHER
Intervention: Blood Tests
Description: If participant received retroviral gene therapy, blood test performed to check for a type of infection called the replication-competent retrovirus (RCR). Blood (up to 4 tablespoons each time) drawn every 3 months for first year after gene transfer therapy and once a year after that.

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Once a year during Years 1-5, questionnaire completions that asks about medical history (general health, the status of any medical conditions, and any illnesses or hospitalizations that may have occurred). It should take about 15-30 minutes to complete.~Once a year during Years 6-15, completion of mailed questionnaire. Participant will be asked about medical history (including if participant has had any children since the infusion) and whether there have been any changes in contact information. The questionnaires should take about 15-30 minutes each time.
Study: NCT02381353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Intraoperative orbital injection of local pain medication

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Intraoperative orbital injection of local pain medication
Study: NCT02003222

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic hematopoietic SCT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic hematopoietic SCT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration
Study: NCT03955055

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Video Capsule Endoscopy
Description: Patients will swallow a video capsule as soon as possible (immediately or within 10 hours, if patient is not fasting).
Study: NCT02707601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E/C/F/TAF
Description: 150/150/200/10 mg fixed dose combination (FDC) tablet administered orally once daily
Study: NCT02003222

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy
Study: NCT02790203

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02707601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F/R/TAF
Description: 200/25/25 mg FDC tablet administered orally once daily
Study: NCT02003222

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study: NCT00603668

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: milatuzumab
Description: two or three times a week dosing of hLL1 for a total of 4 weeks
Study: NCT01939652

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Restrictive VS Standard Fluid Regime

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drag: Crystalloids and Colloids
Study: NCT04193098

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CTL
Description: CTL injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab injection
Study: NCT04527705

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgical root canal retreatment
Description: Non-surgical root canal retreatment

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgical root canal retreatment
Description: Non-surgical root canal retreatment
Study: NCT02019329

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral daily administration from Days 1-12
Study: NCT02003222

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IT, IV, or SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: Given IT, IV, or SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daunorubicin
Description: Given IV
Study: NCT02707601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: 90/400 mg FDC tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: 90/400 mg FDC tablet administered orally once daily
Study: NCT03696446

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Cardiac Rehabilitation Program
Description: This group will receive their Rehab program primarily online through a secure web-based platform with a trained facilitator.
Study: NCT02003222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daunorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV or PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin Calcium
Description: Given IV or PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture
Description: Undergo lumbar puncture

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lumbar Puncture
Description: Undergo lumbar puncture

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mercaptopurine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given PO, IT or IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Given PO, IT or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Given IM or IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegaspargase
Description: Given IM or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Given IV
Study: NCT03696446

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Case Managed Home Program
Description: This group will receive their Rehab program over the phone with a trained facilitator
Study: NCT01249157

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positron Emission Mammography (PEM) and Magnetic Resonance Imaging (MRI)
Description: An additional 5 women will be enrolled at the beginning of the study for training purposes only and will not be included in the assessment of this study. Once the patient has had both breast MRI and PEM, the location of each site of potential breast cancer will be listed for each modality. The location of each abnormality on each imaging examination will be documented. Once the histopathologic evaluation has been performed, the pathology results will be compared to the imaging results for each modality. Furthermore, comparison of the performance of MRI and PEM will then be made with the pathological results as the truth. Comparison of the histology and biomarkers in each lesion detected by each modality will be done in order to determine if these factors affect detection by each modality.
Study: NCT00259519

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Induction of delivery
Description: Induction of delivery
Study: NCT04748913

Intervention type: DEVICE
Group type: OTHER
Intervention: Radiographic examination
Description: Standardized bitewing radiographs will be performed by the principal investigator

Intervention type: DEVICE
Group type: OTHER
Intervention: Scanning with DIAGNOcam
Description: The surface of the selected teeth will be examined under near infrared light using the DIAGNOcam device

Intervention type: DEVICE
Group type: OTHER
Intervention: Scan with DIAGNOcam and Indocyanine
Description: One the dye has been applied, a new series of images will be taken with Diagnocam

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Visual-tactile exploration with separation
Description: The point of contact will be open in the corresponding proximal area of the lesion using an elastic orthodontic separator